Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non–Small-Cell Lung Cancer or Other Tumors

INTRODUCTION: Anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer (NSCLC) is sensitive to ALK inhibitors, but resistance develops. This study assessed the maximum-tolerated dose, safety, pharmacokinetics (PK), and antitumor activity of ceritinib, a novel ALK inhibitor (ALKi), in J...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Thorac Oncol
Prif Awduron: Nishio, Makoto, Murakami, Haruyasu, Horiike, Atsushi, Takahashi, Toshiaki, Hirai, Fumihiko, Suenaga, Naoko, Tajima, Takeshi, Tokushige, Kota, Ishii, Masami, Boral, Anthony, Robson, Matthew, Seto, Takashi
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Lippincott Williams & Wilkins 2015
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4467585/
https://ncbi.nlm.nih.gov/pubmed/26020125
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0000000000000566
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg